| Monday, May 18 2009 |
|
New board members strengthen MIVAC Development’s expertise in commercial pharmaceutical operations and include a voice for the scientists at the MIVAC research center. The company welcomes four new members to the board of directors: Mary Jo Wick, Ola Rönn, Anders Waas, and Johan Westman. |
MIVAC Development has decided to no longer pursue the project for the development of a new vaccine against gastric ulcer and gastric cancer.
Read more >>>
MIVAC Development creates a new company, Toleranzia AB, for the spin-out of the tolerance inducing Re-TolerogenTM platform.
Read more >>>
MIVAC development receives continued financial support from Innovationskontor Väst for the tolerance inducing Re-TolerogenTM platform.
MIVAC Development creates a new company, Alzinova AB, for the spin-out of the AβCCTM-project.
Read more >>>